Copy to clipboard 
TheraCell’s TheraFuze DBF Fiber Bag is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures.
The TheraFuze DBF Fiber Bag is a 100% allograft tissue alternative to the resorbable polymer mesh bag products that are currently on the market. The Fiber Bag is made from cortical demineralized bone fibers and processed using TheraCell’s proprietary Bone Textile™ technology. TheraCell’s TheraFuze DBF processes have been developed to produce uniform fiber geometry, size and texture, and to preserve the natural collagen structure of the allograft. FiberLok™ technology allows the Fiber Bag products to maintain their form and integrity after rehydration, permitting adequate time for manipulation and implantation.
This next-generation posterolateral offering is designed as an alternative to the traditional boat, offering complete containment of added graft material. The Fiber Bag may be packed with autograft or additional allograft material, and the open end of the bag can be sutured for closure following rehydration. The fully contained fiber bag construct may be placed in the posterolateral gutters, in a bone void or cavity, or may be delivered using minimally invasive techniques.
This is the fourth new product in TheraCell’s portfolio of procedure-specific graft solutions to recently be commercialized.
Further, the company announced issuance of U.S. Patent Number 10,639,157 related to the Fiber Bag was issued by the United States Patent and Trademark Office in May 2020.
“The versatility of our technology platform has allowed us to develop and commercialize a range of procedure-specific fiber graft forms to rapidly expand our portfolio of TheraFuze DBF Fiber products,” said Nelson Scarborough, Ph.D., TheraCell’s Chief Scientific Officer, “and the issuance of this new patent further enhances our strong portfolio of intellectual property and demonstrates our ongoing commitment to innovation and leadership in the orthopedic allograft industry.”
TheraCell's TheraFuze DBF Fiber Bag is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures.
The TheraFuze DBF Fiber Bag is a 100% allograft tissue alternative to the resorbable polymer mesh bag products that are currently on the market. The Fiber Bag is made from cortical demineralized bone...
TheraCell’s TheraFuze DBF Fiber Bag is now available for use in spinal and orthopedic surgeries, including minimally invasive procedures.
The TheraFuze DBF Fiber Bag is a 100% allograft tissue alternative to the resorbable polymer mesh bag products that are currently on the market. The Fiber Bag is made from cortical demineralized bone fibers and processed using TheraCell’s proprietary Bone Textile™ technology. TheraCell’s TheraFuze DBF processes have been developed to produce uniform fiber geometry, size and texture, and to preserve the natural collagen structure of the allograft. FiberLok™ technology allows the Fiber Bag products to maintain their form and integrity after rehydration, permitting adequate time for manipulation and implantation.
This next-generation posterolateral offering is designed as an alternative to the traditional boat, offering complete containment of added graft material. The Fiber Bag may be packed with autograft or additional allograft material, and the open end of the bag can be sutured for closure following rehydration. The fully contained fiber bag construct may be placed in the posterolateral gutters, in a bone void or cavity, or may be delivered using minimally invasive techniques.
This is the fourth new product in TheraCell’s portfolio of procedure-specific graft solutions to recently be commercialized.
Further, the company announced issuance of U.S. Patent Number 10,639,157 related to the Fiber Bag was issued by the United States Patent and Trademark Office in May 2020.
“The versatility of our technology platform has allowed us to develop and commercialize a range of procedure-specific fiber graft forms to rapidly expand our portfolio of TheraFuze DBF Fiber products,” said Nelson Scarborough, Ph.D., TheraCell’s Chief Scientific Officer, “and the issuance of this new patent further enhances our strong portfolio of intellectual property and demonstrates our ongoing commitment to innovation and leadership in the orthopedic allograft industry.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
